EA201591251A1 - Характеризация лекарственного продукта, родственного ацетату глатирамера - Google Patents

Характеризация лекарственного продукта, родственного ацетату глатирамера

Info

Publication number
EA201591251A1
EA201591251A1 EA201591251A EA201591251A EA201591251A1 EA 201591251 A1 EA201591251 A1 EA 201591251A1 EA 201591251 A EA201591251 A EA 201591251A EA 201591251 A EA201591251 A EA 201591251A EA 201591251 A1 EA201591251 A1 EA 201591251A1
Authority
EA
Eurasian Patent Office
Prior art keywords
drug
acetate
glatiramer
product related
drug product
Prior art date
Application number
EA201591251A
Other languages
English (en)
Russian (ru)
Inventor
Ривка Шварц
Шломо Бакши
Кевин Дэниел Фаулер
Фади Джордж Тоуфик
Джейсон Майкл Фант
Бенджамин Джеймс Зескинд
Максим Артомов
Original Assignee
Тева Фармасьютикал Индастриз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51061235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201591251(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Тева Фармасьютикал Индастриз Лтд. filed Critical Тева Фармасьютикал Индастриз Лтд.
Publication of EA201591251A1 publication Critical patent/EA201591251A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201591251A 2013-01-04 2014-01-02 Характеризация лекарственного продукта, родственного ацетату глатирамера EA201591251A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361749228P 2013-01-04 2013-01-04
US201361819481P 2013-05-03 2013-05-03
PCT/US2014/010103 WO2014107533A2 (en) 2013-01-04 2014-01-02 Characterizing a glatiramer acetate related drug product

Publications (1)

Publication Number Publication Date
EA201591251A1 true EA201591251A1 (ru) 2016-05-31

Family

ID=51061235

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591251A EA201591251A1 (ru) 2013-01-04 2014-01-02 Характеризация лекарственного продукта, родственного ацетату глатирамера

Country Status (17)

Country Link
US (1) US20140193827A1 (enExample)
EP (1) EP2941274A4 (enExample)
JP (1) JP2016504039A (enExample)
KR (1) KR20150111945A (enExample)
CN (1) CN105228651A (enExample)
AU (1) AU2014204043A1 (enExample)
BR (1) BR112015016169A2 (enExample)
CA (1) CA2896957A1 (enExample)
CL (1) CL2015001915A1 (enExample)
EA (1) EA201591251A1 (enExample)
HK (1) HK1216299A1 (enExample)
IL (2) IL239692A0 (enExample)
MX (1) MX2015008754A (enExample)
PE (1) PE20151980A1 (enExample)
SG (1) SG11201505210RA (enExample)
WO (1) WO2014107533A2 (enExample)
ZA (1) ZA201505367B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598661A (en) 2009-08-20 2013-02-22 Yeda Res & Dev Low frequency glatiramer acetate therapy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CA2814500A1 (en) 2010-10-11 2012-04-19 Teva Pharmaceutical Industries Ltd Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
HK1200274A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
HK1213830A1 (zh) 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. 用於预测醋酸格拉替雷临床反应的生物标志物
CN105377308B (zh) 2013-03-14 2019-07-26 迈兰公司 醋酸格拉替雷响应生物标志物mRNA效力测定
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9995734B2 (en) 2013-10-24 2018-06-12 Mylan Inc. Human T cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
JP2018506275A (ja) 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療
WO2017087866A1 (en) 2015-11-20 2017-05-26 Grand Valley State University Nato3 mutant polypeptides and uses thereof
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
JP7276664B2 (ja) * 2016-11-11 2023-05-18 ロングエバーオン インコーポレイテッド 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
CN115044684A (zh) * 2022-06-22 2022-09-13 四川大学华西医院 lcn2基因作为生物标记物在检测Stat5基因是否缺失中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429374B2 (en) * 2001-12-04 2008-09-30 Teva Pharmaceutical Industries, Ltd. Process for the measurement of the potency of glatiramer acetate
WO2004028339A2 (en) * 2002-09-27 2004-04-08 Brigham And Women's Hospital, Inc. Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
JP2009509142A (ja) * 2005-09-19 2009-03-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 調節性Ｔ細胞機能をモジュレート（ｍｏｄｕｌａｔｅ）し得るＧＰＲ８３アゴニストおよびＧＰＲ８３アンタゴニストを同定するための方法
US8753833B2 (en) * 2007-06-21 2014-06-17 Momenta Pharmaceuticals, Inc. Copolymer assay
EP2365825A1 (en) * 2008-11-18 2011-09-21 Crossbeta Biosciences B.V. Cross-beta structures as carriers in vaccines
NZ598661A (en) * 2009-08-20 2013-02-22 Yeda Res & Dev Low frequency glatiramer acetate therapy

Also Published As

Publication number Publication date
CL2015001915A1 (es) 2016-11-11
BR112015016169A2 (pt) 2017-07-11
KR20150111945A (ko) 2015-10-06
IL252547A0 (en) 2017-07-31
IL239692A0 (en) 2015-08-31
SG11201505210RA (en) 2015-07-30
EP2941274A4 (en) 2016-11-16
PE20151980A1 (es) 2016-01-15
ZA201505367B (en) 2016-11-30
MX2015008754A (es) 2016-04-11
WO2014107533A2 (en) 2014-07-10
EP2941274A2 (en) 2015-11-11
CN105228651A (zh) 2016-01-06
US20140193827A1 (en) 2014-07-10
HK1216299A1 (zh) 2016-11-04
WO2014107533A3 (en) 2015-01-29
AU2014204043A1 (en) 2015-08-13
CA2896957A1 (en) 2014-07-10
JP2016504039A (ja) 2016-02-12

Similar Documents

Publication Publication Date Title
EA201591251A1 (ru) Характеризация лекарственного продукта, родственного ацетату глатирамера
EA201890013A1 (ru) Способы получения tcr гамма дельтат-клеток
MX2023012263A (es) Mejora del efecto de celulas t dise?adas por car por medio de vacunacion con acido nucleico.
CY1121511T1 (el) Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων
EA201791633A1 (ru) Способ точной модификации растения посредством транзиентной экспрессии гена
AR093377A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
CL2013003028A1 (es) Acido ribonucleico interferente que reprime la expresión de genes objetivo en especies de insectos, polinucleótido aislado que lo codifica, constructo de adn, célula huésped, composición que comprende al acido ribonucleico interferente; y método para disminuir la expresión de un gen objetivo en plagas de insectos.
EP3359665C0 (en) EARLY POST-TRANSFECTION ISOLATION OF CELLS TO PREPARE BIOLOGICAL PRODUCTS
EA201890345A3 (ru) Способ получения сахарного спирта из биомассы
WO2014179765A3 (en) Novel human mirnas for use in diagnosis, prognosis and therapy of human conditions and diseases
EA201300454A1 (ru) Клетка дрожжей, сбраживающая пентозу и глюкозу
MY187050A (en) Cancer cell-specific antibody, anticancer agent, and cancer testing method
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
BR112014027905A2 (pt) anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico.
EP3395939A4 (en) CELL SORTING, CULTURE AND GROWTH VESSELS AND CELL SORTING, CULTURE AND GROWTH PROCESSES
EA202091577A1 (ru) Глюкуронилирование в качестве новой кислотной посттрансляционной модификации терапевтических моноклональных антител
UY36197A (es) Caracterización biológica de un producto farmacológico derivado de acetato de glatiramer mediante células de mamífero humano y no humano
MX2017006970A (es) Metodo basado en celulas para determinar la potencia de la defibrotida.
EA201390017A1 (ru) Молекулярно-генетический подход к лечению и диагностике алкогольной и наркотической зависимости
EA201690766A1 (ru) Растворимый fc-гамма рецептор для лечения аутоиммунных буллезных заболеваний
EA201591723A1 (ru) Применение термофильных нуклеаз для разрушения нуклеиновых кислот
MX383010B (es) Bloqueadores del receptor de la hormona del crecimiento en la prevencion y tratamiento de enfermedades.
BR112017009009A2 (pt) método e dispositivo para corrigir um ou mais níveis de expressão, programa(s) para a correção do(s) nível(eis) de expressão de rna(s), meio de gravação legível por computador e chip para análise da expressão de rna pequeno
AR101088A1 (es) Caracterización biológica de un producto farmacológico derivado de acetato de glatiramer mediante células de mamífero humano y no humano
ES2572391T3 (es) Control exógeno interno positivo para la detección de virus